Gene amplification, overexpression, and mutation of human epidermal growth factor receptor 2 (HER2), a transmembrane tyrosine kinase, are observed in approximately 20% of breast cancers and are associated with poor prognosis1,2. Here, ERBB2 is linked to breast carcinoma.